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BEFORE the introduction of the sulphonamide group of drugs, the treatment of
infections due to the gonococcus was largely confined to the use of urinary
antiseptics, irrigations of the urethra, and treatment of complications as they arose.
More recently, vaccines and gonococcal antitoxin were added to these time-honoured
methods in the hope that possibly a more rapid and successful cure might be
attained. Crean (1937) remarks, however, that none of these methods has made any
notable change in the length of time it takes to cure an uncomplicated acute case.
With the introduction of chemotherapy, however, a new era in the treatment of
gonorrheea was ushered in.
Despite the fact that the sulphonamides have now been in use for some three or
four years, there is still considerable doubt on many aspects of the chemotherapeutic
treatment of gonococcal infections, this doubt, in some cases, extending even to the
question as to which is the most suitable preparation to use in the treatment of
these conditions. There is still considerable doubt, too, as to the proper time for
commencing chemotherapy: a number of authorities have advocated "delayed
therapy," whereby chemotherapeutic treatment in acute gonorrhoea is withheld for
some eight to twenty-one days in order to allow the body immunity mechanism to
develop; during this waiting period, routine methods of treatment (i.e., urethral
irrigations and vaccines) are carried out; other workers, on the other hand, com-
mence chemotherapy as soon as the diagnosis of the disease has been established.
Various schemes of dosage have been suggested, whilst difference of opinion still
exists as to the total amount of the drug required and as to the total duration of
treatment, whilst the vexed question of the advisability or otherwise of combining
chemotherapy with routine methods of treatment has not been definitely settled.
Before a satisfactory statement can be made with regard to these points, a
number of considerations demand attention, of which not the least important is the
choice of the drug itself. There is now little doubt that the most efficient sulphona-
mide for use in gonococcal infections is M.&B. 693, and the present article is the
outcome of an investigation made with that drug in the treatment of gonorrhoea
in patients attending the Venereal Diseases Clinic at the Royal Victoria Hospital,
Belfast. The cases investigated were mostly males, though the results obtained
in a small series of female patients are also recorded. In a few cases, Uleron was
the chemotherapeutic agent employed, either per se or before or after the use of
M.&B. 693. Whilst the clinical research was being carried out, a study was also
made of the absorption and excretion of M.&B. 693, and some of the toxic effects of
both M.&B. 693 and Uleron were investigated at the same time. The dosage of the
drugs ultimately employed and the duration of treatment decided upon were the
result of this combined study, the object being to use what was considered to be a
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taking into consideration the toxic reactions produced by the drugs as well as their
absorption and excretion. Some of the results obtained in the more pharmacological
aspects of the investigations are described elsewhere in this issue of the Journal.
PROCEDURE.
The response to treatment in 230 cases of infections due to the gonococcus was
studied. These cases consisted of 216 male and 14 female patients: they were
divided up as follows:
(A) MALE:
I. Treated with M.&B. 693-
(a) Uncomplicated cases 133
(b) Complicated cases - 22
II. Treated with Uleron or Uleron and M.&B. 693 - 19 (11)
(8 of these cases will be discussed with the M.&B.
693 patients, so that actually there are only
11 additional cases).
III. Controls - - - 50
(B) FEMALE - 14
The patients were chosen at random. The desire was to get as large and
representative a series as possible in all stages of the disease, including
a number of patients suffering from a variety of gonococcal complications.
As the use of the drugs and other methods of treatment employed were largely
experimental in the early stages of this research, to discuss the various procedures
adopted would be to anticipate the results of the investigation about to be described.
Such a discussion will be deferred until the various aspects of the clinical results
have been considere(l.
RESULTS.
(A) MALE CASES. I. TREATED WITH M.&B. 693.
(a) UNCOMPLICATED CASES-133 PATIENTS.
In twenty-eight of these patients, symptoms had been present for more than
six weeks, in nine others the duration of the disease was doubtful, the remainder
were "acute" cases, i.e., patients in whom symptoms had been present for less
than six weeks. The actual duration of symptoms before chemotherapy and the
number of patients treated were as follows
Duration of symptoms
before chemotherapy
(days) No. of Patients
1- 7 51
8-14 - - - - 21
15-21 - - - - 14
22- - - - - 38
Doubtful - - - - 9
The final results were divided into four groups
Group 1.-Cured cases or those who passed tests of cure (T.O.C.), and remained
well for a period of two months or longer from the end of chemotherapy.
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to their default before the end of two months from cessation of chemo-
therapy, or who have passed T.O.C. and have been under observation
for a period greater than one month but less than two months from
end of chemotherapy, and are still reporting.
Group 3.-Clinical cures or those who showed a satisfactory response to chemo-
therapy, but who defaulted before T.O.C. or who passed T.O.C. but
defaulted within a month from the end of chemotherapy, or who have
passed T.O.C. and are still under observation, but for a shorter period
than those still reporting in Group 2.
Group 4.-Failures: those patients who failed to respond to one or more courses
of treatment.
T.O.C. were performed at varying intervals after the end of chemo-
therapy. They consisted of provocative doses of gonococcal vaccine
(twenty millions), urethroscopic examination of the anterior urethra, and
the passage of a large sound into the bladder, the urethra being
massaged against the sound.
Eighty-three patients had adjuvant treatment in addition to M.&B. 693, the
remaining fifty having the drug only. The adjuvant treatment consisted of daily
urethral irrigations, usually with 1/10,000 potassium permanganate, and in some
cases weekly injections of gonococcal vaccine were also given. An alkaline powder
was prescribed frequently where nausea following the use of the drug occurred.
A gross analysis of the results reveals the fact that a satisfactory response to
chemotherapy was obtained in 128 cases (or over ninety-six per cent.), there were
five (or 3.7 per cent.) failures, in eight cases (six per cent.) relapses were seen, and
three cases exhibited complications during chemotherapy: the complications were
all mild.
The 128 good results were classified as
Group 1-Cured cases - - - 69
Group 2-Probably cured cases - - 20
Group 3-"Clinical cures" - - - 39
Of the sixty-nine cases in Group 1, fifty-five attended for a period varying from
three to fifteen months from the end of chemotherapy: as in the other two groups,
many of the patients in Group 1 are still reporting at intervals.
The cure-rate was so high in both acute and chronic cases that it seemed evident
that neither "delayed therapy" nor adjuvant treatment made the slightest difference
to the ultimate outcome. In order to confirm this, the failures, relapsed cases, and
cases in whom complications developed during chemotherapy were analysed more
fully.
ANALYSIS OF FAILURES.
Five patients failed to respond to chemotherapy with M.&B. 693. Of these,
chemotherapy was commenced within two to nine days from the onset of symptoms
in two cases, in two others the symptoms were present for six weeks and five and
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Ha half months respectively. The duration of symptoms before chemotherapy in the
fifth case was doubtful, as he had had M.&B. 693 at another centre before reporting
at our clinic: he stated that his discharge had cleared up but had subsequently
recurred. All five cases had adjuvant treatment in addition to chemotherapy. It
was evident, therefore, that in these cases at least, neither "delayed therapy" nor
adjuvant treatment had made any difference to the ultimate outcome.
The cause of the failure was not always evident. In all cases chemotherapy was
more prolonged than usual, whilst in several a larger dose of the drug than usual
was employed, when it was seen that the condition was not responding satisfactorily
to routine dosage. In one of these cases slight cyanosis developed with the increased
dosage; the drug was withheld and the patient put on to routine methods of treat-
ment. Actually, this patient's discharge had cleared up by the second morning on
M.&B. 693, but small threads and pus cells continued to be present in the urine: he
is still on treatment. When increased dosage failed to cure the condition in a
second case, tab. sulphonamide-P (one gramme four times daily) was tried with a
similar unsuccessful result, but the patient complained of such severe nausea and
upset with the sulphanilamide that the drug had to be withheld on the third day.
He too was started on routine measures of treatment, and is still attending the
clinic. Whilst chemotherapy in a third case was again responsible for improve-
ment in symptoms, the urine did not become clear, and continued to show con-
siderable numbers of pus cells. The remaining two cases were treated subsequently
with Uleron, and it was interesting to note that, as in the second case where a
change of sulphonamide failed to produce a satisfactory result, so here a similar
unsatisfactory response to the different sulphonamide was observed. Actually the
discharge in both cases cleared up (after three "stosses" of Uleron in one case and
after two "stosses" in the other), but both cases subsequently defaulted before an
adequate follow-up and when considerable numbers of pus cells were still present
in the urine. In one patient only could a definite cause be found to explain the
chemotherapeutic failure: it was found here that the prostate was slightly enlarged
and tender; daily gentle prostatic massage was instituted just before and during
Uleron therapy, and his condition showed considerable improvement. The cause
of failure in this case was probably due to the prostatitis, a condition to which
Cokkinis and McElligott (1938) attributed a number of their failures with sulpha-
nilamide. What the cause of this condition is, is doubtful, but these workers
consider that it is a gonococcal prostatitis modified by chemotherapy into an
atypical pathology: they have named the condition "sulphonamide prostate."
Apart from the fact that neither "delayed therapy" nor adjuvant treatment had
influenced the results in these cases, a number of other points of interest arose.
In the first place it became evident that where a rapid response to chemotherapy
was not observed, even with increased dosage, continuation of the drug was useless,
whilst it was also interesting to note that where M.&B. 693 had failed to bring
about a successful issue, other sulphonamides were often no more successful. It
has been suggested (Cokkinis and McElligott, 1938) that doses of the sulphonamides
which are inadequate to produce a cure may cause abnormal resistance of the
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have responded if a higher dosage of M.&B. 693 had been given from the onset,
and that the dosage employed had produced a "sulphonamide fast" organism.
Even if this could be proved, in the present state of our knowledge it is impossible
to forecast which patient is going to show this atypical response, but their number
would appear to be so small that it seems to be quite unjustifiable to expose the
majority of patients to the dangers of toxicity which large doses of these drugs
have been found to cause, for the benefit of this small minority.
ANALYSIS OF RELAPSES.
Relapses occurred in eight of the uncomplicated cases of this series, a figure
considerably below that found by other workers (Cokkinis and McElligott, 1939;
Assinder and Knight, 1939; Gardner, 1939). Four of these relapsed twice and four
(one of whom had relapsed after previous Uleron chemotherapy) relapsed once. Of
the four who relapsed twice, two showed an early relapse (symptoms reappearing
five and fifteen days respectively after the end of chemotherapy), in addition to a
"late" relapse eleven months and two and a half months respectively after the end
of all treatment. In the late relapses (i.e., those in whom symptoms reappeared
not earlier than approximately three weeks from the end of chemotherapy), the
interval between the end of chemotherapy and the reappearance of the symptoms
varied from twenty days to eleven months.
The interval between the original onset of symptoms and the first exhibition of
M.&B. 693 had varied considerably: in four cases it had varied from 29 to 188 days,
whilst in the remaining four, the original chemotherapy had been commenced some-
where between the third and the fourteenth day after the appearance of the
symptoms. Three cases had had adjuvant treatment during chemotherapy, whilst a
fourth had had urethral irrigations and vaccines for some considerable time before
M.&B. 693 had been started. So that here again, neither "delayed therapy" nor
adjuvant treatment appeared to play any vital part in the prevention of the relapse.
This is rather at variance with the suggestion put forward by Cokkinis and McElli-
gott (1939) that one cause for late relapses is the too early commencement of
chemotherapy. These workers also consider that too short chemotherapy may
likewise play a part in producing these relapses. In the series under discussion,
relapses occurred in three of the early cases treated, when a more prolonged use of
the drug as well as a larger dose were being employed than were used subsequently:
whilst the maximum duration of the original chemotherapy in these cases was ten
days, if too short chemotherapy were responsible for the reappearance of the
symptoms, one would have expected a much higher percentage of late relapses in
cases treated subsequently.
In three cases, relapses occurred after large amounts of alcohol, whilst in two
cases, attendance during chemotherapy had been irregular. Whilst a vigorous
denial of re-exposure was almost invariably given, one was suspicious that the
reappearance of symptoms in one or two cases at least was the result of a fresh
infection.
In these late relapses, the symptoms were often not typical of an acute infection:
83usually the patient complained of being damp, and on examination, urethral
moisture rather than discharge was seen; this was often gonococcal negative. The
urine became slightly hazy again and showed a reappearance of threads and pus
cells. Where a copious urethral discharge was seen and where other symptoms
typical of an acute attack were present, one was suspicious that the "relapse" was
in reality a fresh infection. The symptoms and signs of the early relapse were
essentially similar to those of the original attack.
Most of these cases responded satisfactorily to a second course of M.&B. 693,
though one case required a much heavier dosage and more prolonged treatment
than usual before his symptoms cleared up. Three cases defaulted either in the
middle of treatment or before adequate follow-up after chemotherapy: it was
interesting to note that these three patients had been irregular attenders during
previous chemotherapy.
A point of importance, and one that has been stressed by Cokkinis and
McElligott (1939), is the fact that many of the patients in whom symptoms of late
relapse occur had passed tests of cure successfully following their first course of
treatment. From the facts recorded, it is suggestive that the most rigorous tests
of cure in gonorrheea are indulgence in alcohol by the patient, and a prolonged
follow-up after the end of chemotherapy. A prolonged follow-up has been the aim
in this investigation, but unfortunately, in many cases, the patients failed to
reappear a short time after the end of chemotherapy.
Even allowing for the fact that many patients defaulted before adequate follow-
up, it seems evident that the relapse-rate with sulphonamide therapy is very much
lower than following routine methods of treatment. An analysis of fifty cases of
patients treated by routine methods will be referred to later; suffice it to say here
that a relapse-rate of twenty-six per cent. was observed in the controls. That a
high percentage of defaulters will report when symptoms reappear is evident from
the fact that, of the eight relapsed cases discussed here, no fewer than three had
defaulted before adequate follow-up after their first course of treatment. The views
of a number of workers, therefore, as to the increased dangers of "gonococcal
carriers" being at large as a result of these late sulphonamide relapses, hardly
seems to be justified. Rather would it appear evident that the number of relapses
is enormously reduced, and the possibilities of gonococcal carriers very much less,
than in pre-sulphonamide days.
ANALYSIS OF CASES DEVELOPING COMPLICATIONS DURING CHEMOTHERAPY WITH
M.&B. 693.
Complications were seen in three cases only. Two patients developed prostatitis
and a third complained of "rheumatism." This last patient had had a previous
attack of gonorrhoea some two years earlier, and had suffered from "rheumatism"
then, too: the pains in the second attack, when M.&B. 693 was being employed,
were much less severe than previously.
Cokkinis and McElligott (1938) had a complication-rate of eight per cent. in their
series of cases of gonorrhoea treated by sulphanilamide, and of thirty-six per cent,
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analysed personally, tweinty-four per cent. developed complicationis during routine
treatment: this is rather lower than the figure found by Cokkinis and McElligotl
(1938), but it is evident that gonococcal complications are greatly reduced with
M.&B. 693, not only as compared witlh complicatioins (levelopinig during routine
treatment, but also as compared with those developinig (lurinig sulphanilamide
therapy.
(b) CONIPLICATED CASES-21 PATl'IENTlS.
In twenty-one male patients treated with M.&B. 693, complications were present
before chemotherapy was commenced: these were
(iroup A. 17 cases:
Epididymitis - - - - 11 cases
Prostatitis - - - - 3 cases
Conjunctivitis, periurethral abscess, anid
retetntion overfloow (each) - - 1 case
(iroup B.-4 cases of arthritis.
It was a significant feature that out of the seventeen patients in Group A, no less
than fourteen had had previous treatment by routine methods, whilst in the case
of the remaining three patients, previous routine therapy may also have been
employed, as the complication was present when these patients first reported at the
cliniic. In eight of these seventeen cases, chemotherapy was commenced three
weeks after the onset of symptoms of the acute attack of gonorrhcea, whilst in the
remainder, the interval between the onset of symptoms and the beginning of chemo-
therapy varied from two to sixteen (lays. Iwo cases of arthritis occurred xvithin a
few days from the beginning of the acute attack of gonorrhcea, whilst in the
remaining twvo, the symptoms of arthritis had been present for two to three years.
It has been mentioned that various workers have recommended a waiting period
of from eight to twenty-one days from the onset of the symptoms of gonorrhcea
until the beginning of chemotherapy, treatment in this period being confined to
urethral irrigations and vaccines. That complications occurred in eight out of the
seventeen patients in Group A dluring this interval, when urethral irrigations and
in some cases vaccines were being employed, is a significant reply to those who
advocate such a waiting period with adjuvant treatment before chemotherapy.
In discussing delayed therapy in connection with Uleron treatment of gonorrhcea,
Marinkovitch (1939) states that some twenty per cent. of his cases developed
complications mostly towards the end of the second week of treatment and before
chemotherapy was commenced.
GONOCOCCAL COMPLICATIONs-EPIDIDYMITIS.
In every case, the symptoms of the complication showedl an almost dramatic
improvement with chemotherapy : this was most marked in the epiclidymitis cases.
Almost always, the pain in these cases had gone by the morning following the
beginning of chemotherapy, whilst the tenderness was usually gone by the third
morning. Several of these cases still showed some residual thickening of the
epi(lidvmis at the end( ol chemotherapy, but this almost invariably disappeared
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was the improvement in one case that the patient actually defaulted in the middle
of treatment: he re-attended subsequently whep sent for, and reported perfectly fit.
Whilst this gratifying result was observed with the complications, the urethral
discharge recurred in a number of cases as the epididymitis subsided or within a
short time afterwards: in two cases the task of curing the discharge proved difficult
with subsequent treatment: one of the cases not only showed a recurrence of his
urethral discharge, but also developed an epididymitis on the opposite side from
his original attack, ten days after withdrawal of M.&B. 693. Tab. sulphonamide-P
(one gramme four times daily) was administered, but the discharge not only
persisted but became more copious, whilst the epididymis increased in size, though
the pain and tenderness were considerably eased. This patient defaulted before
further adequate treatment.
The second patient showed a continuation of the urethral discharge throughout
chemotherapy with M.&B. 693. Response to subsequent treatment with Uleron was
also unsatisfactory, but he responded rapidly to a short course of urethral irriga-
tions with 1/10,000 potassium permanganate following chemotherapy. These two
cases have been termed chemotherapeutic failures, though it must be remembered
that the complication for which the chemotherapy was originally instituted in each
case was very greatly improved. It is possible, however, that a focus of infection
may still have been present at the site of the complication.
Two other cases showed a "late" relapse, two months and twenty-four days
respectively from the end of chemotherapy. One of these patients was showing a
satisfactory response to routine treatment when he defaulted, the other case showed
a rapid response to a further course of M.&B. 693. The first of these two patients is
considered a chemotherapeutic failure, as his response to M.&B. 693 (though the
drug caused a rapid improvement in his epididymitis) was unsatisfactory: he
continued to complain of morning discharge in the interval between the end of
chemotherapy and his relapse. Another patient again showed the same rapid
improvement of his epididymitis, but defaulted a few days after the end of chemo-
therapy and when the urine was still showing threads and some pus cells: he, too,
is considered as an M.&B. 693 failure, although his condition probably cleared up
satisfactorily.
GONOCOCCAL COMPLICATIONS-VARIOUS.
Of the various complications in Group A, the origin of the conjunctivitis was
doubtful, and no gonococci were found in the conjunctival sac: the conjunctivitis
and accompanying urethral discharge cleared up rapidly with M.&B. 693, but it is
possible that the eye condition would have shown an equally ready response to the
adjuvant treatment of argyrol and atropine per se. In the case of the periurethral
abscess, incision and drainage were followed by a rapid amelioration in symptoms,
whilst the urine became sterile a few days after the first exhibition of M.&B. 693.
Twice-daily catheterisation was necessary to relieve the retention overflow during
the first two days in the sixth case of this series: this treatment alone in another
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693, however, appeared to bring about a successful issue within a few days.
GONOCOCCAL COMPLICATIONS-ARTHRITIS.
As in the other complications, the amelioration of symptoms in both acute and
chronic gonococcal arthritis was often quite dramatic, and all cases at least showed
an improvement.
One case was particularly interesting: this man had had symptoms of arthritis,
especially affecting his wrist and hand joints, off and on for two years. M.&B. 693
was started (three grammes daily) and continued for four days, after which time it
was withdrawn on account of toxic symptoms. The pains had improved greatly,
but recurred slightly following cessation of chemotherapy. A further three grammes
per day were given for three more days. He reported at intervals for a further four
months. By the end of three months he stated that in the interval he had been
able to "go hard at it" from 9 a.m. until 6 p.m.: this was the first time he had
been able to work like this since the onset of his complaint.
Dosage of the drug in all these complicated cases was largely experimental, but
it was found, as before, that very often an equally good result was obtained by
comparatively small doses as that obtained with larger ones, though in the case of
arthritis, chemotherapy was usually carried on for a considerably longer period
than in the other complications. It again became evident that where a satisfactory
response to sulphonamide therapy was not obtained within the first day or two, a
failure was almost certainly inevitable. Despite this, the continuation of chemo-
therapy in the case of complications would appear to be justified, at least for a
number of days, as the response of the complication was almost always so grati-
fying. It again became evident, too, that failure with M.&B. 693 was frequently
followed by failure with other sulphonamides.
Adjuvant treatment was employed occasionally. In addition, in almost every
case of epididymitis, support for the affected organ was insisted upon.
That failure to respond to chemotherapy is due in part to poor absorption of the
drug, became evident from the study of the absorption and excretion of M.&B. 693
in some of those cases where an unsatisfactory response was seen. Apart from the
poor absorption of the drug, however, another obvious cause for chemotherapeutic
failure and relapse in gonorrhoea becomes evident from the study of these compli-
cations. Four out of seventeen (23.5 per cent.) of these cases (excluding the patients
suffering from arthritis) were ultimate failures with sulphonamide therapy, despite
marked improvement in the complications complained of, whilst two cases (almost
twelve per cent.) were "late" relapses. It is possible that some at least of the
failures or late relapses recorded by other workers may be due to a slight compli-
cation which had been overlooked, and it would appear to be advisable that where a
chemotherapeutic failure or relapse is recorded, a thorough examination be made
for any possible complication, however slight.
Since failure and relapse are thus more common in complicated than uncompli-
cated cases, another point in favour of early chemotherapy becomes evident, since
it has been shown that gonococcal complications do not usually occur where the
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Kdisease is confined to the anterior urethra, but become comparatively frequent when
the posterior urethra becomes involved.
II. TREATED WITH ULERON ONLY OR ULERON AND M.&B. 693.
Space does not permit any detailed description of the cases treated by Uleron
nor were the results sufficiently encouraging to justify a long report. Several points
of interest arose. In the first place, the average cure with Uleron was somewhere
between fifty and sixty per cent., a figure very much below that obtained with
M.&B. 693, whilst the average total duration of treatment was considerably longer
than with that drug. It again became evident that where one drug failed, the results
obtained with the other were often no more encouraging, though this was not
invariable. "Delayed chemotherapy" and adjuvant treatment gave rather better
results when used in conjunction with Uleron than when Uleron was used alone.
III. CONTROLS-50 PATIENTS.
The fifty control patients were chosen at random from those cases who had been
treated by routine methods of daily urethral irrigations and weekly injections of
gonococcal vaccine. In order to obtain a better general perspective of the results
of routine treatment, these cases were chosen from a series who had been treated
before the introduction of sulphonamide therapy for gonorrheea.
The only criteria which were looked for in the cases chosen as controls were
that the patients had attended reasonably well during treatment, and that they had
been subsequently discharged as cured.
They were analysed, in the main, from three aspects
(1) Duration of treatment.
(2) Percentage of relapses occurring.
(3) Percentage of complications arising during treatment.
The average duration of treatment in the fifty cases was just over three months.
Actually, several cases attended for treatment for from four and a half to nine
months. Thirteen cases, or twenty-six per cent., showed relapses, whilst twelve
cases, or twenty-four per cent., developed complications during treatment.
Comment is unnecessary when these figures are compared with the results
obtained with chemotherapy.
(B) FEMALE CASES-14 PATIENTS.
Not only is gonorrhoea in the female patient difficult to treat, but the organism,
especially in old standing cases, is difficult to isolate and culture. An attempt was
made to isolate and culture the organism in most of the cases treated, but this was
often unsuccessful, and the condition was treated as the result of the clinical
diagnosis of acute or chronic gonorrhoea. Unfortunately, the female is much less
tolerant than the male to the sulphonamides, and nausea and vomiting are com-
paratively frequent, so that co-operation in chemotherapy is often more difficult to
obtain than in men. Moreover, the series here considered is rather small for any
definite conclusions to be reached as to the appropriate dosage of the drug required,
the necessity or otherwise of adjuvant treatment, and the ultimate result following
chemotherapy in the female. The results obtained even from this small series
leave little doubt that the response of gonococcal conditions to chemotherapy
88in the female is as encouraging (given favourable conditions) as in the male.
Whilst most of the cases treated at least showed considerable improvement in
their condition (only one failing to do so), several are of special interest.
One was a woman of 33 years of age, who had had a heavy vaginal discharge
following a confinement seven years previously: the discharge had become worse
during the last three years, during which time she had had conservative treatment
off and on. She was started on M.&B. 693 (0.5 grammes four times daily) and
chemotherapy was continued for fourteen days. At the beginning of chemotherapy
there was pus in the urethra, a heavy vaginal discharge, and the cervix was eroded:
when M.&B. 693 was withdrawn, the discharge had ceased and the cervical erosion
was greatly improved. The improvement was not only maintained, but became
more pronounced, and two months later the patient stated that for the first time
for three years she had been able to do without a vulval pad: on examination the
only pathology seen was a slight cervical erosion. She subsequently became
pregnant after an interval of seven years, during which time she stated that no
contraceptive methods had been employed. Unfortunately, she developed a high
blood pressure and albuminuria, and the pregnancy had to be terminated at the
seventh month: the infant did not live.
Two other cases failed to respond to the oral administration of M.&B. 693, but
shoowed satisfactory progress when intramuscular preparations of the drug were
used in conjunction with the tablets. It is probable that oral administration alone
was insufficient to give a sufficiently high concentration of the drug in the blood to
be really effective in these two cases, and that this was overcome only when the
more readily absorbed preparations were used. The second patient was an irregular
attender, and that this was also partly responsible for the failure to respond to
oral therapy alone is not unlikely, and experience would tend to show that con-
tinuous treatment is highly important when chemotherapy is being employed.
Two cases were victims of gonococcal arthritis before chemotherapy. Both
responded well to M.&B. 693, though one showed a subsequent relapse; the relapse
was accompanied by less severe pain than was experienced at the earlier attack.
ADMINISTRATION OF THE DRUGS AND ADJUVANT TREATMENT.
M.&B. 693.
Various schemes of dosage of M.&B. 693 were tried in the early part of this
work, and had to be abandoned or modified for one reason or another. A con-
siderably larger dose was used at the beginning than is now employed, but it was
found that minor toxic reactions with these larger doses were comparatively
frequent and patients complained of headache, nausea, flatulence, and many other
unpleasant minor reactions. A number of patients then defaulted in the middle
of chemotherapy, after having had a much smaller quantity of M.&B. 693 than
the majority of cases: some of these defaulters reported subsequently and were
found to have been perfectly well in the interval. In addition, from the study of
the toxicity of the drug (a summary of which is described elsewhere in this Journal),
it soon became evident that M.&B. 693 was much more toxic than early experi-
mental evidence had promised. A consideration of these facts suggested that not
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being employed, but that such a modification was highly desirable if the possibility
of serious toxic reactions was to be reduced to a minimum. Dosage was subse-
quently reduced, and it was gratifying to find that not only was the frequency of
minor toxic reactions much less, but the clinical response was equally good.
The dosage finally decided upon in the treatment of acute and chronic uncom-
plicated gonorrhoea in the male was 3 gm. of the drug on the first.day, the drug
being taken in divided doses at intervals which were considered to be sufficient
to give a reasonably steady blood concentration, i.e., 1 gm. immediately after
examination (about 10 a.m.), 0.5 gm. at 2 p.m., 0.5 gm. at 6 p.m., and 1 gm. at
bedtime. The following six days, 0.5 gm. four times daily, was taken at approxi-
mately the same time as on the first day. After seven days' treatment the drug
was withheld. It was occasionally found that a few small specks were still present
in the urine, but these usually cleared up within a few days' time without further
treatment. When the specks persisted or when symptoms reappeared (which was
seldom), a further seven-day course similar to the first was started.
Where disappearance of the discharge was not seen by the second or third day,
the dose was increased (provided no toxic symptoms were seen), as it was considered
that the failure to respond to routine dosage was possibly due to poor absorption
of the drug. If this procedure was still rewarded by failure (which again was
seldom), or where signs of toxicity followed the use of the larger doses, the drug
was withheld and other sulphonamides were administered or routine treatment
was instituted.
In complicated cases a similar dosage was often found to be equally effective,
though treatment was sometimes more prolonged (especially in arthritis cases)
than in uncomplicated cases.
Thus dosage and the duration of chemotherapy are considerably less than those
recommended by the majority of workers, but the results obtained and the other
factors considered would appear to more than justify their continuance.
That the treatment of the female was made more difficult on account of the
greater susceptibility to the toxic effects of the drug in this sex than in the male
has been mentioned. Unfortunately, decreasing the dosage of the drug in the
female was not followed by the same encouraging decreasAe in "minor" toxic
symptoms as was observed in the case of men, and other methods for overcoming
these unpleasant effects were adopted. These included giving the tablets suspended
in, or in combination with, glucose or alkalis or in giving a smaller dose at more
frequent intervals (i.e., half a tablet every two hours rather than a whole tablet
every four hours). These methods were followed by success of varying degree in
different patients, but no hard and fast rule could be laid down to avoid toxicity in
all cases, and in some patients, all efforts resulted in failure to avoid nausea or
vomiting or both. In these cases, as in the males, the drug was stopped and
another sulphonamide was given or routine measures of treatment adopted. It was
found, on the whole, that more prolonged dosage was necessary in the treatment
of gonorrhoea in the female than in the male, and that less toxicity was observed
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treated were given 0.5 gm. of M.&B. 693 four times daily (or 0.25 gm. two-hourly)
for fourteen days where possible.
ULERON.
Uleron was administered in doses of 3 gm. per day for four days, followed by a
perio(d of seven to eight days' rest, when a second "stoss" similar to the first was
given, and after a further interval of rest as before, a third similar "stoss" was
administered. The minor toxic reactions due to this drug were found to be much
less common than with M.&B. 693, but the major toxic possibilities were found to
be just as serious. In addition, adequate treatment with the drug was found to be
much more prolonged and tedious than with M.&B. 693, and the clinical results
less convincing. As a result, Uleron has only been used in the treatment of a
comparatively few cases.
The broad outline upon which treatment and follow-up were based was as
follows:-
With a male patient, on his first appearance at the clinic, the history was taken
and a careful note of the clinical condition was made. A smear was taken from the
urethral discharge and in a number of cases the discharge was cultured: the smear
was stained by the Gram method and examined for the gonococcus. Where a
syphilitic infection was suspected as well, a drop of serum from the suspected
chancre was examined by darkground illumination: if this was positive, arsenical
treatment was at once instituted, and the gonococcal infection was treated by
routine methods, as it was considered unwise to employ two drugs together, either
of which was capable of causing agranulocytosis per se. In one case only were
M.&B. 693 and neoarsphenamine employed together, and no ill-effects resulted.
Actually, a rapid response to treatment was observed in both diseases in this
patient, though the gonorrhoea was longer in clearing up with M.&B. 693 than
usual.
Where chemotherapy was decided upon, the patient was told to avoid all sulphur-
containing foods and to use only mild laxatives, when any laxative was necessary,
and he was warned to abstain from alcohol and sexual excitement until such times
as his condition was cured. The-following day chemotherapy was commenced with
the chosen drug, and the patient was seen daily during the time the drug was being
taken, only one day's supply of tablets being given at each visit. On each visit a
smear and, in a number of cases, a culture also were made where possible from the
urethral discharge, until such times as the discharge became gonococcal negative:
in many cases, however, the discharge had cleared up by the following morning,
whilst in others it was very much reduced, and almost always no gonococci were
found. Where there was no discharge present, a sample of urine was centrifuged
and the centrifuged deposit examined for the organism. At the end of chemotherapy,
a further sample of urine was similarly examined, and the patient told to report in
three to four days' time, and if everything was satisfactory, to report at weekly
intervals for a further period. This follow-up period varied, the aim being to see
the patient at intervals for as long a time as possible, and at least for a further
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to one visit in two weeks and then one visit per month. At varying intervals after
the end of chemotherapy, tests of cure (T.O.C.) were performed to see whether or
not the condition could reasonably be regarded as cured. In addition to the T.O.C.
already described, alcohol was now permitted. The patient was seen twenty-four
to forty-eight hours after T.O.C., and a further sample of urine was centrifuged
and the deposit examined. If everything was satisfactory, he was told to report as
stated above. Frequent urinary examinations were performed during the follow-up
period.
T.O.C. are now performed from ten to twenty days from the end of
chemotherapy.
With Uleron, the main line of treatment was similar to that for M.&B. 693 except
that smears from the urethral discharge or a centrifuged deposit of urine were
examined before and after and on the second day of each "stoss," or, where the
discharge persisted, a daily smear was examined for the gonococci until the
discharge became gonococcal negative.
In the case of females, a careful vaginal and bi-manual examination were per-
formed and smears and culture from the urethra, Bartholin's glands, or the cervix
were made. It has been mentioned, however, that these were often negative, and
the condition was treated as a result of the clinical diagnosis of acute or chronic
gonorrhoea. Follow-up and adequate tests of cure were very much more unsatis-
factory than in the male.
The procedures described above are, in the main, those now adopted in the
treatment of gonorrhoea at the Venereal Diseases Clinic of the Royal Victoria
Hospital, Belfast. Three other things remain to be said.
It has been shown that adjuvant treatment makes little difference to the ultimate
outcome of acute cases of gonorrhoea treated by M.&B. 693. Whilst this is true
in the majority of cases, one or two patients did show a more rapid response to
treatment when urethral irrigations were employed after the first day or two of
chemotherapy alone. In addition, it was felt that possibly the use of urethral
irrigations might help to prevent the high default-rate which was evident when
chemotherapy only was used. As a result, on his first appearance at the clinic and
during chemotherapy, the patient is now given urethral irrigations of 1 in 10,000
permanganate potassium in addition to M.&B. 693.
A further point of importance is, that during the follow-up period the patient's
blood is examined to exclude the possibility of syphilis. The tests performed are
the Wassermann reaction (using the Harrison and Fleming techniques), and, where
a doubtful positive result is obtained, a Dreyer flocculation test is also carried out.
Finally, one method suggested by Wilkie (1939) to combat defaulters is that
patients should be requested by letter to reattend hospital when they fail to reappear
after an interval. The majority of defaulters in the present investigation were
requested to reattend for re-examination once, twice, or even three times, but only
a very small percentage turned up and frequently they again defaulted. In many
cases the communications sent were returned as "not known" or "wrong address" '
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(1) The use of M.&B. 693 and Uleron in the treatment of gonococcal infections has
been compared with routine methods.
(2) Over ninety-six per cent. of uncomplicated cases of gonorrhoea are cured by
M.&B. 693 in one-twelfth the time, and fifty to sixty per cent. are cured by
Uleron in one-third the time taken by routine methods of treatment.
(3) Complications with M.&B. 693 are reduced to one-eighth of those developing
during routine treatment.
(4) Six per cent. of M.&B. 693 cases showed late relapses: the symptoms of the
late relapse are described and their significance discussed. Several of these
cases relapsed more than once.
(5) In complicated cases, marked relief from symptoms is observed within a short
time from taking M.&B. 693 or Uleron. The ultimate failure and relapse-rate
are higher in complicated than in uncomplicated cases.
(6) An analysis of failures, relapses, and complications arising during chemotherapy
in uncomplicated cases, together with an analysis of the treatment of compli-
cated cases, showed that with M.&B. 693, adjuvant treatment is unnecessary
and "delayed therapy" is not only unnecessary but undesirable. Rather better
results are obtained with Uleron where adjuvant treatment and "delayed
therapy" are employed.
(7) Some reasons for failure to respond to chemotherapy are suggested.
(8) Failure with one sulphonamide is often followed by failure withl another, though
this is not invariable.
(9) A plan for the management of gonococcal infections including administration
and dosage of M.&B. 693 is described, and the importance of adequate
follow-up is stressed.
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